Want to see SE:FLUO full AI Analyst Report?

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr31.00

-kr1.20(-3.69%)

At close: Jul 27 4:00 PM EDT

kr31.00

-kr1.20(-3.69%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.80

Previous CloseN/A

Volume5.16K

Average Volume (3M)3.94K

Market Cap

kr539.53M

Enterprise Valuekr653.63

Total Cash (Recent Filing)kr49.92M

Total Debt (Recent Filing)kr27.56M

Price to Earnings (P/E)―

Beta0.25

Next Earnings

Nov 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.00

Shares Outstanding16,349,314

10 Day Avg. Volume3,369

30 Day Avg. Volume3,939

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-3.46

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused Oncology Imaging PlatformThe company targets a clear surgical need: improving tumor visualization while sparing healthy tissue. A focused oncology imaging platform could support differentiated clinical value if FG001 demonstrates efficacy and gains regulatory approval.

Multiple Commercialization PathwaysThe model offers more than one route to future commercialization. Product sales could create recurring per-dose revenue, while licensing or partnerships may provide external development support and milestone or royalty income.

Positive Equity And Asset BufferPositive equity and a sizeable asset base provide some balance-sheet support while the company advances its clinical program. This buffer may help preserve operating flexibility, although it does not remove the need for additional financing.

Bears Say

Minimal And Declining RevenueVery limited and declining revenue shows that the business has not yet established commercial scale. This leaves results dependent on clinical execution and future approvals, increasing the risk that operating costs will remain unsupported.

Heavy Cash BurnLarge operating and free-cash-flow deficits indicate that the company is not self-funding its activities. Continued clinical development will likely require financing, creating dilution or funding risk if capital access becomes constrained.

Rising Leverage And Persistent LossesDebt has risen close to the equity base while substantial losses continue, reducing financial flexibility. If losses persist, the capital base could weaken and obligations may increase reliance on external funding or restructuring.

FluoGuide A/S News

FluoGuide’s FG001 Phase 2 Trial Targets Sharper Brain Tumor Surgery and New Value for Investors

FluoGuide A/S ($SE:FLUO) announced an update on their ongoing clinical study. FluoGuide A/S (FLUO) is launching a Phase...

4M ago

FLUO

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.80 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr539.53M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Nov 26, 2026 which is in 63 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on Aug 25, 2026. The company reported -kr1.142 earnings per share for the quarter.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.142 in its last earnings report. Following the earnings report the stock price went up 7.395%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.